EBV-reactivation and Posttransplant Lymphoproliferative Disorder Treated with Rituximab
We read the recent paper on profile of EBV-associated infectious mononucleosis (IM) by Balasubramanian, et al. [1] with interest. They concluded that EBV associated IM is more common in preschool children. Here we highlight another dreaded complication due to reactivation of EBV post-allogeneic stem cell transplant (SCT) leading to post-transplant lymphoproliferative disorder (PTLD). Mortality rates due to PTLD are reported to be as high as 50-90% [2] . Various therapeutic approaches are suggested for EBV-associated PTLD including anti-B-cell treatments such as rituximab (Anti-CD20 monoclonal antibody) [3] . Rituximab alone or combined with low-dose chemotherapy is an effective therapy for EBV-associated PTLD [4, 5] . We describe here successful treatment of EBV induced PTLD with rituximab in an infant post-allogeneic SCT.
An 11-month-old girl was referred to our centre for matched sibling allogeneic SCT. She was diagnosed as a case of familial hemophagocytic lymphohistiocytosis (HLH) at the age of three months and treated as per HLH-2004 protocol. Her elder brother was complete 6/6 match with her on HLA typing. She received reduced intensity conditioning regimen and her doner stem cells (CD34 positive cells) were infused. GVHD prophylaxis consisted of cyclosporine and methotrexate. She had neutrophil and platelets engraftment on Day +22 and +26, respectively. FISH studies performed on day +30 showed 97% XY (donor) cells and 3% XX (recipient) cells.
On day +45, she developed high grade fever and neck swelling with difficulty in swallowing. Bilateral tonsils were enlarged. Hepatosplenomegaly was also noted. A possibility of PTLD due to EBV was considered. Her EBV DNA copy numbers were raised to 72700. She was started on injection rituximab 375 mg/m 2 IV weekly × 4 doses. Her fever disappeared 48 hours later and tonsils gradually became normal size by day +52. Her repeat EBV DNA copy numbers were 1900 after 3 weeks. She was discharged on day +81 post-transplant and is doing well till date (18 months post-transplant). Early detection of EBV induced PTLD and aggressive treatment with Rituximab is a key to survival in patients who have undergone allogeneic SCT. 
